Eli Lilly’s Zepbound (tirzepatide) delivered 20.2% average body weight reduction in the SURMOUNT-5 head-to-head trial, compared to 13.7% for Novo Nordisk’s Wegovy (semaglutide 2.4 mg). The FDA approved Wegovy for chronic weight management in June 2021, and Zepbound followed in November 2023. Both medications are once-weekly subcutaneous injections, but Zepbound activates two hormone receptors (GIP and GLP-1) while Wegovy targets only GLP-1. In the 72-week SURMOUNT-5 study published in 2025, 31.6% of Zepbound patients hit 25% total body weight loss versus 16.1% on Wegovy.
The SURMOUNT-1 trial enrolled 2,539 adults with obesity and showed Zepbound’s highest dose (15 mg) produced 22.5% average body weight loss over 72 weeks. Wegovy’s pivotal STEP-1 trial followed 1,961 participants and documented 14.9% average weight loss at 68 weeks. Both drugs carry a black box warning for thyroid C-cell tumors based on rodent studies, and both require gradual dose escalation over 16 to 20 weeks to reduce gastrointestinal side effects. Patients typically notice appetite suppression within 4 to 8 weeks, though maximum weight loss continues through month 18.
This guide compares Zepbound and Wegovy across mechanism of action, clinical trial outcomes, side effect profiles, dosing schedules, cost, insurance coverage, and real-world results. At Green Relief Health in Baltimore, Dr. Lauren Nawrocki and her team prescribe both medications through a comprehensive medical weight loss program after a full metabolic evaluation. The right choice depends on your starting BMI, medical history, insurance formulary, and response to initial dosing.
What’s Inside
How Zepbound and Wegovy Work Differently
Zepbound and Wegovy belong to the same drug class (incretin mimetics) but act on different receptors. Tirzepatide, the active ingredient in Zepbound, binds two gut hormone receptors simultaneously. Semaglutide, the active ingredient in Wegovy, binds only one. This mechanistic difference explains the larger weight loss seen in Zepbound trials.
Zepbound’s Dual-Action Mechanism
Zepbound activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GIP suppresses appetite, improves insulin sensitivity, and reduces food intake. GLP-1 slows gastric emptying, increases satiety, and lowers blood sugar. Activating both receptors produces a synergistic effect on appetite and metabolism. Dr. Ania Jastreboff and colleagues reported in the New England Journal of Medicine (2022) that Zepbound reduced daily caloric intake by roughly 600 calories in SURMOUNT-1 participants.
Wegovy’s GLP-1 Only Approach
Wegovy delivers semaglutide at 2.4 mg weekly, which is higher than the 1.0 mg maximum used in Ozempic for type 2 diabetes. The drug slows stomach emptying, signals fullness to the hypothalamus, and reduces food cravings. Wegovy was the first once-weekly GLP-1 agonist approved specifically for chronic weight management in adults with a BMI of 30 or greater, or 27 with at least one weight-related condition like hypertension or dyslipidemia. Read our complete Wegovy guide for the full clinical background.
Clinical Trial Results: SURMOUNT and STEP Data
Head-to-head trials and pivotal studies provide the clearest evidence for comparing these two drugs. Each medication was approved based on separate Phase 3 programs, then directly compared in the SURMOUNT-5 study.
SURMOUNT-1: Zepbound’s Pivotal Trial
SURMOUNT-1 randomized 2,539 adults with obesity (mean BMI of 38) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. After 72 weeks of treatment, the 15 mg group lost 22.5% of body weight on average, the 10 mg group lost 19.5%, and the 5 mg group lost 15.0%. The placebo arm lost only 2.4%. Roughly 36% of patients on the 15 mg dose achieved 25% or greater total body weight loss, a benchmark historically reserved for bariatric surgery outcomes.
STEP-1: Wegovy’s Pivotal Trial
STEP-1 enrolled 1,961 non-diabetic adults and assigned them to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, the semaglutide group lost 14.9% of body weight on average compared to 2.4% for placebo. About 32% of Wegovy patients reached 20% or more weight loss, and 50.5% achieved at least 15%.
SURMOUNT-5 Head-to-Head Comparison
SURMOUNT-5 directly compared tirzepatide and semaglutide in 751 adults with obesity or overweight. At 72 weeks, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide, a 47% relative advantage for Zepbound. Patients on tirzepatide lost an average of 50.3 pounds compared to 33.1 pounds for semaglutide.
| Trial Metric | Zepbound 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Average weight loss (pivotal) | 22.5% | 14.9% |
| Head-to-head result (SURMOUNT-5) | 20.2% | 13.7% |
| Trial duration | 72 weeks | 68 weeks |
| Participants with 15% or more loss | 78% | 50.5% |
| Participants with 25% or more loss | 36% | 16.1% |
Side Effect Profiles Compared
Both medications share a similar side effect footprint because they act on overlapping receptors. Gastrointestinal complaints dominate reported adverse events, and most occur during dose escalation.
Gastrointestinal Reactions
Nausea is the most common complaint for both drugs, though the exact frequencies differ slightly by dose and titration speed. The following table compiles frequencies from the highest approved doses of each medication.
| Side Effect | Zepbound 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Nausea | 29% | 44% |
| Diarrhea | 23% | 30% |
| Constipation | 17% | 24% |
| Vomiting | 13% | 24% |
| Abdominal pain | 10% | 20% |
| Injection site reaction | 6% | 3% |
Black Box Warning and Serious Adverse Events
Both Zepbound and Wegovy carry a boxed warning for medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN 2). Rodent studies showed an increased risk of thyroid C-cell tumors, though human data remains inconclusive. Patients with a personal or family history of these conditions cannot take either drug. Pancreatitis, gallbladder disease, and acute kidney injury have also been reported with both medications.
Dosing Schedules and Titration
Both drugs require gradual dose escalation to minimize gastrointestinal symptoms. The target dose typically arrives after 16 to 20 weeks of incremental increases.
Zepbound Dose Escalation
Zepbound comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard schedule starts at 2.5 mg weekly for the first four weeks, then increases by 2.5 mg every four weeks until the maintenance dose. Prescribers often stop at 5 mg, 10 mg, or 15 mg based on patient response and tolerance. Read more about how Zepbound works for weight loss in our detailed breakdown, or explore our tirzepatide program for candidacy and pricing.
Wegovy Dose Escalation
Wegovy offers five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The titration schedule moves patients from 0.25 mg to 2.4 mg over 16 weeks, with each dose lasting four weeks. Unlike Zepbound, Wegovy has only one maintenance target at 2.4 mg, though some patients remain on 1.7 mg if they cannot tolerate the higher dose.
Cost, Insurance, and Access
Price and coverage often drive the final prescription decision, especially for patients paying out of pocket or facing insurance denials.
List Price Comparison
As of early 2026, Zepbound’s cash price runs approximately $1,086 per month for any dose, while Wegovy lists at roughly $1,349 per month. Eli Lilly launched a vial program offering Zepbound single-dose vials at $349 for 2.5 mg and $499 for 5 mg, making it the cheaper option for self-pay patients. Novo Nordisk has not released a similar vial discount program.
Insurance Coverage Differences
Commercial insurance coverage varies widely. Some employer plans cover Wegovy but not Zepbound, others cover both, and many exclude weight loss drugs entirely. Medicare does not cover either medication for obesity, though Part D plans may cover Wegovy for cardiovascular risk reduction following its March 2024 approval for that indication.
Choosing Between Zepbound and Wegovy
No single answer fits every patient. The decision depends on medical history, treatment goals, insurance, and personal preferences.
When Zepbound May Be the Better Choice
Patients seeking maximum weight loss, those with type 2 diabetes, and individuals who previously tried GLP-1 only drugs without success often respond better to Zepbound’s dual-receptor action. The drug also offers more dose flexibility with six strengths, which helps providers fine-tune your response over time.
When Wegovy May Be the Better Choice
Wegovy may fit patients with established cardiovascular disease because the FDA approved it in March 2024 to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and existing heart disease. Zepbound does not yet carry this indication. Patients whose insurance only covers semaglutide-based drugs also benefit from choosing Wegovy. For deeper comparisons across the GLP-1 category, see our Wegovy vs Mounjaro and Wegovy vs Ozempic guides.
Ready to Find the Right GLP-1 for You?
Book a consultation with Dr. Lauren Nawrocki and the Green Relief Health team to review your candidacy for Zepbound or Wegovy.
Book a ConsultationFinal Thoughts
Zepbound and Wegovy represent the two most effective FDA-approved weight loss medications on the market in 2026. Zepbound delivers greater average weight loss based on both SURMOUNT-1 and SURMOUNT-5 head-to-head data, with patients losing roughly 22.5% of body weight at the 15 mg dose compared to 14.9% on Wegovy. The difference reflects tirzepatide’s dual-receptor mechanism, which activates both GIP and GLP-1 pathways simultaneously.
Wegovy remains a strong option for patients with cardiovascular disease, those who respond well to GLP-1 only therapy, or individuals whose insurance formulary favors semaglutide. Both drugs share similar gastrointestinal side effects, carry identical black box warnings, and require the same gradual dose titration. The right choice depends on your specific medical history, BMI, and treatment response.
At Green Relief Health in Baltimore, Dr. Lauren Nawrocki evaluates every weight loss candidate with a full metabolic panel, medical history review, and personalized dosing plan. Our team prescribes both Zepbound and Wegovy alongside nutritional guidance and hormone optimization therapy when indicated. Patients who experience facial volume loss during significant weight reduction sometimes benefit from complementary treatments like dermal fillers or Kybella injections for submental contouring.
Frequently Asked Questions
Yes, Zepbound produced greater weight loss in the SURMOUNT-5 head-to-head trial. Patients on tirzepatide lost 20.2% of body weight over 72 weeks compared to 13.7% on semaglutide. Zepbound’s 15 mg dose also produced 22.5% average loss in SURMOUNT-1, the highest weight loss ever recorded in a major weight management drug trial. The difference comes from tirzepatide activating both GIP and GLP-1 receptors while semaglutide targets only GLP-1.
Yes, switching is possible and commonly done when Wegovy response plateaus. Most providers start Zepbound at the 2.5 mg starter dose one week after the last Wegovy injection, even if the patient was on a higher Wegovy dose. The titration schedule restarts to allow the body to adjust to tirzepatide’s different receptor profile. Discuss timing with your provider to avoid overlap or gaps in appetite suppression.
Zepbound produces slightly lower rates of nausea, vomiting, and constipation at its highest dose compared to Wegovy. In trial data, 29% of Zepbound users reported nausea versus 44% for Wegovy, though individual responses vary widely. Both drugs cause similar rates of gallbladder issues and pancreatitis. Slow titration and dietary adjustments reduce symptoms for most patients on either medication.
Both medications are designed for long-term use, and stopping leads to weight regain in most patients. The STEP-1 extension trial showed participants regained about two-thirds of lost weight within a year of stopping Wegovy. SURMOUNT-4 documented similar regain patterns after discontinuing Zepbound. Most obesity specialists consider these drugs chronic therapy similar to blood pressure or cholesterol medications.
Zepbound’s list price runs about $1,086 per month, while Wegovy costs roughly $1,349 per month. Eli Lilly offers Zepbound vials at $349 to $499 per month for self-pay patients, which reduces out-of-pocket costs substantially. Manufacturer savings cards can lower commercial insurance copays to as little as $25 monthly for eligible patients. Call (410) 368-0420 to verify coverage options through the clinic’s verification process.
Both drugs improve blood sugar, blood pressure, cholesterol, and obstructive sleep apnea severity. Zepbound received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity based on the SURMOUNT-OSA trial. Wegovy received cardiovascular risk reduction approval in March 2024 for patients with established heart disease. Both medications reduce A1C by roughly 2 percentage points in patients with type 2 diabetes.
Yes, both medications pair well with nutritional counseling, exercise programs, and medical spa treatments. Patients losing significant weight sometimes experience loose skin or facial volume changes and benefit from volume restoration treatments. Combining GLP-1 therapy with hormone optimization can also address weight loss resistance in perimenopausal women and men with low testosterone.
Most patients notice appetite suppression within the first 2 to 4 weeks and visible weight loss by week 8. Maximum effect typically occurs between months 12 and 18 as patients reach their target dose and sustain weight loss momentum. The average Zepbound patient loses about 1.5 pounds per week during active titration, while Wegovy users average 1 pound per week. Results vary based on starting weight, diet adherence, and physical activity level.
Start Your Weight Loss Journey Today
Green Relief Health in Baltimore offers both Zepbound and Wegovy with a full metabolic evaluation, personalized dosing, and ongoing support from Dr. Lauren Nawrocki.
Book a Consultation
